Amicus Therapeutics(FOLD) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year GalafoldQ3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti+ Opfolda Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, NJ, November 6, 2024 – Amicus Therapeutics (Nas ...